Vir Biotechnology and Britain’s GSK said on Wednesday they planned to seek emergency use authorisation for their experimental Covid-19 antibody therapy after interim data from a study showed 85 per cent reduction in hospitalisation and deaths among patients.
An independent panel recommended stopping further enrolment for the late-stage trial due to evidence of “profound efficacy” of the therapy, Vir and GSK said in a joint statement.
Also read: Researchers develop antibodies cocktail that could fight all forms of Covid-19
Antibody treatments are designed to decrease the severity of Covid-19 among patients diagnosed with the infection.
Additionally, the companies said a new laboratory study showed the therapy, VIR-7831, was equally effective against the UK, South African and Brazilian variants of the coronavirus.
Vir and GSK announced a partnership last year to research Covid-19 treatments.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.